Should we cease to perform salvage hysterectomy after chemoradiation and brachytherapy in locally advanced cervical cancer?

Cyrus Chargari, Erica Bentivegna, Alexandra Leary, Catherine Genestie, Amandine Maulard, Philippe Morice, Sebastien Gouy, Marie Gosset

    Research output: Contribution to journalArticlepeer-review

    15 Citations (Scopus)

    Abstract

    Background/Aim: We evaluated patients undergoing salvage hysterectomy after brachytherapy (BT) following concomitant chemoradiation (CRT) for locally advanced cervical cancers (LACC), when residual disease was suspected. Patients and Methods: From 2004 to 2013, 29 patients had a radical hysterectomy at the Gustave Roussy for suspicion of clinical and/or radiological residual disease. Outcomes, morbidities and the accuracy of the evaluation of response to CRT and BT were evaluated. Results: The rate of complications grade>IIIa was 24%, with no difference between the 14 patients with histological residual disease and the 15 with a complete response. Magnetic resonance imaging (MRI) and positron emission tomography-computed tomography (PET-CT) revealed a sensitivity of 92% and 100%, but a poor specificity of less than 40%. Three recurrences occurred in patients with residual disease (brain, rectosigmoid colon, peritoneum and lung). Conclusion: The clinical examination, MRI and PET-CT are suboptimal for diagnosing residual disease after CRT and BT. The morbidity of adjuvant hysterectomy is high and does not prevent recurrences.

    Original languageEnglish
    Pages (from-to)2919-2926
    Number of pages8
    JournalAnticancer Research
    Volume39
    Issue number6
    DOIs
    Publication statusPublished - 1 Jan 2019

    Keywords

    • Brachytherapy salvage hysterectomy
    • Chemoradiation therapy
    • Locally advanced cervical cancer
    • Morbidity

    Cite this